Diagnostic and prognostic needs in neurodegenerative disorders: Focus on proteomics

Expert Review of Proteomics

Volumn 5, Issue 2, 2008, Pages 153-156

  Bibl, Mirko ^a   Wiltfang, Jens ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN TISSUE; CHEMOLUMINESCENCE; DEGENERATIVE DISEASE; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROGNOSIS; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

BIOLOGICAL MARKERS; HUMANS; NEURODEGENERATIVE DISEASES; PROGNOSIS; PROTEINS; PROTEOMICS;

EID: 43449097573     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.5.2.153     Document Type: Editorial

References (27)

1. Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to Alzheimer's disease. Brain 129, 2840-2855 (2006).
2. Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol. Aging 18, 85-88 (1997).
3. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122, 1131-1135 (1984).
4. Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl Acad. Sci. USA 83, 4044-4048 (1986).
5. Vandermeeren M, Mercken M, Vanmechelen E et al. Detection of proteins in normal an Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem. 61, 1828-1834 (1993).
6. Blennow K, Wallin A, Ågren H et al. Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer's disease? Mol. Chem. Neuropathol. 26, 231-245 (1995).
7. Motter R, Vigo-Pelfrey C, Kholodenko D et al. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38, 643-648 (1995).
8. The Working Group on: 'Molecular and Biochemical Markers of Alzheimer's Disease', Consensus report of the Working Group on: 'Molecular and Biochemical Markers of Alzheimer's Disease'. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol. Aging 19, 109-116 (1998).
9. Dubios B, Feldman HW, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734-746 (2007).
10. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1, 213-225 (2004).
11. Shoji M, Matsubara E, Kanai M et al. Combination assay of CSF tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease. J. Neurol. Sci. 158, 134-140 (1998).
12. Hulstaert F, Blennow K, Ivanoiu A et al. Improved discrimination of AD-patients using β-amyloid (1-42) and tau levels in CSF. Neurology 52, 1555-1562 (1999).
13. Maddalena A, Papassotiropoulos A, Mueller-Tillmanns B et al. Cerebrospinal fluid amyloid β42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. Arch. Neurol. 60, 1202-1206 (2003).
14. Lewczuk P, Esselmann H, Otto M et al. Neurochemical diagnosis of Alzheimer's dementia by CSF Ab42, Ab42/Ab40 ratio and total tau. Neurobiol. Aging 25, 273-281 (2004).
15. Wiltfang J, Esselmann H, Bibl M et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem. 81, 481-496 (2002).
16. Bibl M, Mollenhauer B, Esselmann H et al. CSF amyloid-β- peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 129, 1177-1187 (2006).
17. Bibl M, Mollenhauer B, Esselmann H et al. CSF diagnosis of Alzheimer's disease and dementias with Lewy bodies. J. Neural Transm. 113, 1771-1778 (2006).
18. Bibl M, Mollenhauer B, Wolf S et al. Reduced CSF carboxyterminally truncated A? petides in frontotemporal lobe degenerations. J. Neural Transm. 114, 621-628 (2007).
19. Bibl M, Mollenhauer B, Lewczuk et al. Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias. Mol. Psychiatry 12, 671-680 (2007).
20. Hansson O, Zetterberg H, Buchhave P et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5, 228-234 (2006).
21. Lewczuk P, Kornhuber J, Vanderstichele H et al. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol. Aging PMID: 17239996 (2007) (Epub ahead of print).
22. Wiltfang J, Esselmann H, Bibl M et al. Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho-Tau in patients with low- and high-CSF A β 40 load. J. Neurochem. 101, 1053-1059 (2007).
23. van Oijen M, Hofman A, Soares HD et al. Plasma Aβ(1-40) and Aβ(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 5, 655-660 (2006).
24. Bibl M, Esselmann H, Mollenhauer B et al. Blood-based neurochemical diagnosis of vascular dementia: a pilot study. J. Neurochem. 103, 467-474 (2007).
25. Ray S, Britschgi M, Herbert C et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13(11), 1359-1362 (2007).
26. Lewczuk P, Kornhuber J, Wiltfang J. The German Competence Net Dementias: standard operating procedures for the neurochemical dementia diagnostics. J. Neural Transm. 113, 1075-1080 (2006).
27. Lewczuk P, Beck G, Ganslandt O et al. International quality control survey of neurochemical dementia diagnostics. Neurosci. Lett. 409, 1-4 (2006).